Abstract

Aiming to expand its presence in Europe as well as its business in regenerative medicines, Hitachi Chemical will acquire Apceth Biopharma, a German contract manufacturer, for about $85 million. The deal follows Hitachi’s purchase of PCT, a US regenerative medicines contractor, in 2017 and the opening of a contract development and manufacturing facility in Yokohama, Japan, last April. Apceth specializes in producing cancer immunotherapy cells, induced pluripotent stem cells, and mesenchymal stem cells.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call